Morphic Holding (Morphic Holding) Change In Receivables : $0.51 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding Change In Receivables?

Morphic Holding's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Morphic Holding's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Morphic Holding's change in receivables for the fiscal year that ended in Dec. 2023 was $0.46 Mil. It means Morphic Holding's Accounts Receivable declined by $0.46 Mil from Dec. 2022 to Dec. 2023 .

Morphic Holding's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Morphic Holding's liquidation value for the three months ended in Mar. 2024 was $639.58 Mil.

Morphic Holding Change In Receivables Historical Data

The historical data trend for Morphic Holding's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding Change In Receivables Chart

Morphic Holding Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-3.47

-3.85

5.01

1.85

0.46

Morphic Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.05	0.51	-	-	-

Morphic Holding Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.51 Mil.

Morphic Holding (NAS:MORF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Morphic Holding's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Morphic Holding's accounts receivable are only considered to be worth 75% of book value:

Morphic Holding's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	658.766	-	19.185	+	0.75 * 0	+	0.5 * 0
=	639.58

Morphic Holding Change In Receivables Related Terms

Thank you for viewing the detailed overview of Morphic Holding's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Morphic Holding (Morphic Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (NAS:MORF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

31Y:Germany 31Y:Germany

Address

35 Gatehouse Drive, A2, Waltham, MA, USA, 02451

Website

http://www.morphictx.com

Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.

Executives

William Devaul	officer: General Counsel and Secretary	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Bruce Rogers	officer: Chief Scientific Officer	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Marc Schegerin	officer: CFO and COO	ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Praveen P. Tipirneni	director, officer: President and CEO	C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Farrell Robert E Jr	officer: VP Finance and Ops, Secretary	CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Joseph P Slattery	director	C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Timothy A Springer	director, 10 percent owner	36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Peter Linde	officer: Chief Medical Officer	C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE A2, WALTHAM ME 02451
Nisha Nanda	director	281 TRESSER BOULEVARD, STAMFORD CT 06901
Amir Nashat	director	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p.	director	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Vikas Goyal	director	C/O SR ONE, LTD., 161 WASHINGTON ST., SUITE 500, EIGHT TOWER BRIDGE, CONSHOHOCKEN PA 19428
Otello Stampacchia	director	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199